Skip to main content

Smoflipid Dosage

Generic name: SOYBEAN OIL 6g in 100mL, MEDIUM-CHAIN TRIGLYCERIDES 6g in 100mL, OLIVE OIL 5g in 100mL, FISH OIL 3g in 100mL
Dosage form: injection, emulsion
Drug class: Intravenous nutritional products

Medically reviewed by Drugs.com. Last updated on May 12, 2022.

2.1 Important Administration Instructions

  • SMOFlipid is prepared and administered by a healthcare provider in the inpatient setting. Patients and caregivers may prepare and administer SMOFlipid for home use after appropriate training by a trained healthcare provider.
  • SMOFlipid is for central or peripheral intravenous infusion only.
  • SMOFlipid admixtures with osmolarity
    • Greater than or equal to 900 mOsm/L must be infused through a central vein.
    • Less than 900 mOsm/L may be administered either through a central or peripheral vein.
  • Use a 1.2 micron in-line filter during administration.
  • Use a dedicated infusion line without any connections. Do not connect multiple medications in series.
  • To prevent air embolism, use a nonvented infusion set or close the vent on a vented set and fully evacuate residual gas in the bag prior to administration.
  • Do not pressurize the flexible bag to increase flow rates, and if administration is controlled by a pumping device, turn off the pump before the bag runs dry.
  • Do not use infusion sets and lines that contain di-2-ethylhexyl phthalate (DEHP), including infusion sets that contain polyvinyl chloride (PVC) components, because they contain DEHP as a plasticizer.
  • SMOFlipid can be infused concurrently into the same vein as dextrose-amino acid solutions (as part of PN) by a Y-connector located near the infusion site; flow rates of each solution should be controlled separately by infusion pumps.
  • After connecting the infusion set, start infusion of SMOFlipid immediately. Complete the infusion within 12 hours when using a Y-connector and within 24 hours when used as part of an admixture.

2.2 Preparation Instructions

Use the following instructions to prepare single-dose SMOFlipid 100 mL, 250 mL, and 500 mL Flexible Containers for administration:

Figure
1. Inspect Bag
  • Inspect the integrity indicator (Oxalert®) (A) before removing the overpouch.
  • Discard the product if the indicator is black, overpouch is opened or damaged, emulsion color is not white, or seals of bag are broken.
Figure
2. Remove Overpouch
  • Place the bag on a clean, flat surface.
  • Tear overpouch at notch and pull down.
  • Discard the Oxalert sachet (A) and the oxygen absorber (B).
  • Visually inspect the bag and contents for particulate matter and discoloration prior to administration. The lipid emulsion should be a homogenous liquid with a milky white appearance. If the mixture is not white or the emulsion has separated (noted by discoloration, phase separation, or oily droplets), or if particulates and/or leakage are observed, discard the bag.
Figure
Figure


3. Spike Bag
  • Identify the infusion port (blue cap with the arrow pointing away from the bag).
  • Immediately before inserting the infusion set, break off the blue infusion port cap.
  • Use infusion sets according to ISO Number 8536-4 with an external spike diameter of 5.5 to 5.7 mm and use a nonvented infusion set or close the air-inlet on a vented set.
  • Use a 1.2 micron in-line filter for administration.
  • Hold the base of the infusion port.
  • Insert the spike through the infusion port by rotating your wrist slightly until the spike is inserted.
  • Do not pierce the infusion port more than once.
Figure
4. Hang the bag
  • On the hanger cut and start infusion.
  • Discard unused portion.

SMOFlipid 100 mL, 250 mL and 500 mL single-dose Flexible Containers

  • After removing the overpouch, infuse immediately. If not used immediately, the product should be stored at 2°C to 8°C (36°F to 46°F) for no longer than 24 hours. After removal from storage, infuse within 12 hours when using a Y-connector and within 24 hours when used as part of an admixture.

SMOFlipid 1000 mL Pharmacy Bulk Package

  • For admixing use only and not for direct intravenous infusion. Prior to administration, transfer to a separate PN container for individual patient use.
  • Transfer the contents through the blue infusion port using a suitable sterile transfer device or dispensing set. Discard any unused contents.
  • Use the Pharmacy Bulk Package immediately for admixing after removal from overpouch. If not used immediately, the product can be stored for no longer than 24 hours at 2°C to 8°C (36°F to 46°F). After removal from storage, and once the closure is penetrated, use Pharmacy Bulk Package contents within 4 hours.

Admixing Instructions

  • Prepare the admixture in PN containers using strict aseptic techniques to avoid microbial contamination.
  • Do not add SMOFlipid to the PN container first; destabilization of the lipid may occur. The prime destabilizers of emulsions are excessive acidity (such as a pH <5) and inappropriate electrolyte content. Amino acid solutions exert buffering effects that protect the emulsion from destabilization. Give careful consideration to the addition of divalent cations (Ca++ and Mg++), which have been shown to cause emulsion instability.
  • Do not inject additives directly into SMOFlipid.
  • SMOFlipid may be mixed with amino acid and dextrose injections to produce “all-in-one” PN admixtures. The mixing sequence below must be followed for manual compounding to minimize pH-related problems by ensuring that typically acidic dextrose injections are not mixed with lipid emulsions alone; shake bags gently after each addition.
    • Transfer dextrose injection to the PN container.
    • Transfer amino acid injection.
    • Transfer SMOFlipid.
  • Simultaneous transfer of amino acid injection, dextrose injection, and SMOFlipid to the PN container is also permitted; follow automated compounding device instructions as indicated. Use gentle agitation during admixing to minimize localized concentration effects.
  • Additions to the PN admixtures should be evaluated by a pharmacist for compatibility. Questions about compatibility may be directed to Fresenius Kabi USA, LLC.
  • Inspect the admixture to ensure that precipitates have not formed during preparation of the admixture and the emulsion has not separated. Discard the admixture if any of the above are observed.
  • Infuse admixtures containing SMOFlipid immediately. If not used immediately, store admixtures under refrigeration at 2°C to 8°C (36°F to 46°F) for no longer than 24 hours. Infusion must be complete within 24 hours after removal from refrigeration. Discard any remaining admixture.
  • Protect the admixed PN solution from light.

2.3 Recommended Dosage and Administration

  • The dosing of SMOFlipid depends on the patient's individual energy requirements influenced by age, body weight, tolerance, clinical status, and the ability to metabolize and eliminate lipids.
  • When determining dose, energy supplied by dextrose and amino acids from PN, as well as energy from oral or enteral nutrition, has to be taken into account. Energy and lipid provided from lipid-based medications should also be taken into account (e.g., propofol).
  • Prior to administration of SMOFlipid, correct severe fluid and electrolyte disorders and measure serum triglyceride levels to establish a baseline value. In patients with elevated triglyceride levels, initiate SMOFlipid at a lower dosage and titrate in smaller increments, monitoring the triglyceride levels with each adjustment [see Warnings and Precautions (5.7)]. SMOFlipid contains 0.162 to 0.225 mg/mL of all-rac-alpha-tocopherol. Take into account the amount of all-rac-alpha-tocopherol in SMOFlipid when determining the need for additional supplementation.

Recommended Adult Dosage

  • The recommended dosage of SMOFlipid for adult patients is 1 to 2 g/kg/day and should not exceed 2.5 g/kg/day. The initial rate of infusion should be 0.1 g/minute for the first 15 to 30 minutes of infusion. If tolerated, gradually increase until reaching the required rate after 30 minutes. Maximum infusion rate should not exceed 0.1 g/kg/hour. The daily dose should also not exceed a maximum of 60% of total energy requirements [see Overdosage (10)].
  • The recommended duration of infusion for SMOFlipid is between 12 and 24 hours, depending on the clinical situation. The administration flow rate is determined by dividing the volume of lipid by the duration of the infusion.

Recommended Pediatric Dosage

  • The recommend dosage of SMOFlipid for pediatric patients is shown in Table 1.
  • The duration of infusion will vary depending on the clinical situation, but infuse SMOFlipid over a longer duration in neonates as shown in Table 1.
  • Do not exceed an infusion rate of 0.15 g/kg/hour.
  • The administration flow rate is determined by dividing the volume of lipid by the duration of the infusion.
Table 1: Recommended Pediatric Dosage

* The neonatal period is defined as including term, post-term, and preterm newborn infants. The neonatal period for term and post-term infants is the day of birth plus 27 days. For preterm infants, the neonatal period is defined as the day of birth through the expected age of delivery plus 27 days (i.e., 44 weeks post-menstrual age).

Pediatric Age group Initial Dose Maximum Dose Duration of infusion
Birth to 2 years of age (including preterm and term neonates*) 0.5 to 1 g/kg/day

Increase the dose by 0.5 to 1 g/kg/day
3 g/kg/day 20 to 24 hours for preterm and term neonates

12 to 24 hours for patients
1 month to 2 years
2 to <12 years of age 1 to 2 g/kg/day

Increase the dose by 0.5 to 1 g/kg/day
3 g/kg/day 12 to 24 hours
12 to 17 years of age 1 to 2 g/kg/day 2.5 g/kg/day 12 to 24 hours

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.